3. Menopause Hormone Therapy (MHT/HRT): Principles and Prescribing
Pedagogy: This lesson uses longitudinal management planning — building the skill of annual review, dose adjustment, and the shared decision-making conversation about continuation or cessation of HRT.
Learning Objectives
- State that there are no arbitrary time limits for HRT duration
- Describe the annual review framework: effectiveness, side effects, bleeding, benefit-risk balance
- Discuss the evidence on gradual dose reduction vs abrupt cessation
- Outline monitoring requirements: blood pressure, breast screening, bleeding patterns
Key Facts
Duration of Treatment
The BMS states that systemic HRT should be continued for as long as benefits outweigh risks. There are no arbitrary time limits. For POI, HRT should continue at least until age 51 (average natural menopause age). The decision to continue or stop should be individualised and based on ongoing shared decision-making (1,2).
Annual Review Framework
BMS recommends: review at 3 months after commencing or changing HRT, then at least annually. Each review should assess: effectiveness and side effects; bleeding pattern; type and dose adequacy; ongoing benefit-risk balance. Routine serum oestradiol measurement is NOT required but may help in women with poor symptom control or POI (1).
Discontinuation
VMS may recur in up to 87% of women after stopping HRT. There is no definitive evidence-based guideline on optimal discontinuation method. Options include gradual dose reduction over 3-6 months or abrupt cessation. The IMS 2025 notes the decision should be individualised (2).
HRT Beyond Age 60
The ESE guideline recommends that women who wish to continue MHT beyond age 60 or more than 10 years post-menopause should have an individual risk assessment. The absolute risks of breast cancer and cardiovascular events increase with age, but so does the absolute benefit for bone protection and quality of life (2).
Clinical Pearl There are NO arbitrary time limits for HRT. The '5-year rule' is a myth. Annual review of benefit-risk balance is what matters — not a calendar deadline.
Clinical Pearl VMS recur in up to 87% of women on stopping HRT. When discussing discontinuation, set realistic expectations. Some women will need long-term treatment.
Case-Based Examples
Case 1: 58-year-old at annual HRT review — should she continue?
Presentation: A 58-year-old has been on transdermal HRT for 7 years. VMS are well-controlled. BP normal, BMI 26, no new risk factors. She asks: 'My friend's GP told her to stop after 5 years. Should I stop?'
Question: How do you approach this annual review conversation?
Model Answer: Reassure: there is no 5-year rule. BMS 2026: continue as long as benefits outweigh risks. At her annual review: assess symptom control (excellent), side effects (none), BP (normal), breast screening (up to date), bleeding pattern (amenorrhoea on ccHRT). Calculate updated breast cancer risk: at 7 years, the attributable risk is higher than at 5 years but the absolute increase is modest. Discuss: quality of life benefit vs small absolute risk. If she wishes to continue, document the shared decision. Offer: she could try a gradual dose reduction to see if symptoms have resolved, but warn that 87% of women experience VMS recurrence.
Case 2: 63-year-old wanting to continue HRT — specialist considerations
Presentation: A 63-year-old has been on HRT since age 51 (12 years). She tried stopping twice and VMS returned within weeks. She has well-controlled hypertension and BMI 31.
Question: What factors influence the decision to continue HRT beyond age 60?
Model Answer: Beyond age 60: absolute risks of breast cancer, CVD, and stroke increase with age. ESE 2025: individual risk assessment. Her considerations: 12 years of combined HRT = higher attributable breast cancer risk; BMI 31 + hypertension = cardiometabolic risk (but transdermal HRT is safe for these). Benefits: sustained quality of life, ongoing bone protection. Management: ensure transdermal route (already appropriate given BMI/BP), lowest effective dose, annual review including mammography and CVD risk assessment. Consider if she would accept fezolinetant as an alternative. Ultimately, this is a shared decision — document clearly. Specialist referral is appropriate if GP is uncertain.
Self-Assessment Questions
PLAB/MLA Duration of HRT
Which statement about HRT duration is CORRECT per current guidelines?
A. HRT should be stopped after 5 years in all women
B. There are no arbitrary time limits; continue as long as benefits outweigh risks
C. HRT must be stopped at age 60
D. HRT duration should not exceed 10 years
Answer: B. BMS 2026: no arbitrary time limits. Individualised annual review of benefit-risk balance.
MRCGP Managing a patient who wants to stop HRT
A 54-year-old on HRT for 4 years wants to stop. She is worried about side effects of coming off. What do you advise?
A. Stop abruptly — there are no withdrawal effects
B. Reduce dose gradually over 3-6 months; warn that VMS may recur in up to 87% of women
C. She must continue HRT indefinitely
D. Switch to fezolinetant before stopping
Answer: B. Gradual dose reduction over 3-6 months is commonly used, though no method is definitively evidence-based. Warn about VMS recurrence (up to 87%). If symptoms return significantly, she can restart. The decision is hers.
Professor HRT beyond age 60 — evidence and guideline tensions
A healthy 64-year-old on long-term HRT asks about continuing. Evaluate the evidence base for HRT use beyond age 60.
A. All guidelines agree HRT should stop at 60
B. ESE recommends individual risk assessment; absolute risks increase with age but so do quality-of-life benefits; no RCT data specifically address continuation beyond 60 vs de novo initiation at this age
C. WHI proves HRT is safe at any age
D. There is no evidence to inform this decision
Answer: B. The WHI enrolled women with mean age 63, but this was de novo initiation, not continuation. Observational data suggest women who have been on HRT long-term and then stop experience significant quality-of-life decline. ESE 2025: individual risk assessment beyond 60. The evidence gap is that no RCT has studied continuation vs cessation in long-term users aged >60. Clinical pragmatism: lowest effective dose, transdermal route, annual review, documented shared decision.
Take-Away Messages
- No arbitrary time limits for HRT — continue as long as benefits outweigh risks (BMS 2026)
- Review at 3 months after initiation, then at least annually: efficacy, side effects, bleeding, benefit-risk balance
- Routine serum oestradiol is NOT required; may be useful in POI or poor symptom control
- VMS recur in up to 87% on stopping — set realistic expectations
- Beyond age 60: individual risk assessment (ESE 2025); use lowest effective dose, transdermal route, document shared decision